Improvement of medication adherence for desmopressin by adjusting the prescription dosage in male patients with overactive bladder: A claims database analysis

被引:0
|
作者
Tsubouchi, Kazuna [1 ]
Maeda, Toshiki [2 ]
Emoto, Taiki [1 ]
Aoyagi, Chikao [1 ]
Matsuoka, Wataru [1 ]
Yamazaki, Fumihiro [1 ]
Nakagawa, Chizuru [1 ]
Fukuhara, Yuichiro [1 ]
Tominaga, Kosuke [1 ]
Gunge, Naotaka [1 ]
Miyazaki, Takeshi [1 ]
Okabe, Yu [1 ]
Matsuzaki, Hiroshi [1 ]
Nakamura, Nobuyuki [1 ]
Arima, Hisatomi [2 ]
Haga, Nobuhiro [1 ]
机构
[1] Fukuoka Univ, Fac Med, Dept Urol, 7-45-1 Nanakuma, Fukuoka 8140180, Japan
[2] Fukuoka Univ, Fac Med, Dept Prevent Med & Publ Hlth, Fukuoka, Japan
关键词
adherence; desmopressin; overactive bladder;
D O I
10.1002/nau.25541
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesDesmopressin is widely used for nocturia in patients with nocturnal polyuria. We investigated the continuation rate and adherence for desmopressin in patients with overactive bladder and nocturia using a claims database and evaluated factors that improved adherence.MethodsPatients with nocturia in a Japanese claims database who started desmopressin between September 2019 and July 2021 were evaluated. Drug persistence was assessed using the Kaplan-Meier method for initial prescription of desmopressin. The proportion of days covered (PDC) was also evaluated among patients with prescription persistence. Multivariate analysis was performed using logistic regression analysis to identify factors predicting adherence to desmopressin.ResultsThe study included 72,888 patients entered into Japan Medical Data Center (JMDC) database between September 2019 and July 2021. For the 236 patients prescribed desmopressin formulations, mean prescription duration was 114 days. Among the total cases, 90 (38.1%) cases were prescribed only once, mean PDC was 0.60, and the number of high-adherence patients (PDC >= 0.80) was 108 (45.8%). Desmopressin prescription doses were fixed in 216 patients and adjusted in 20 patients. Multivariate analysis identified prescription dose adjustment for desmopressin as significantly associated with high PDC.ConclusionDesmopressin showed a 38% dropout rate after the first dose. However, high medication continuation and high medication adherence rates (PDC) could be maintained with prescription adjustments. Careful patient monitoring and appropriate adjustment of the desmopressin dosage appear to be important factors in improving nocturia.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Overactive Bladder Medication Adherence When Medication is Free to Patients
    Sears, Christine L. G.
    Lewis, Christa
    Noel, Kathleen
    Albright, Todd S.
    Fischer, John R.
    [J]. JOURNAL OF UROLOGY, 2010, 183 (03): : 1077 - 1081
  • [2] REAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSIS
    Staskin, David
    Chastek, Benjamin
    Carrera, Adam
    Landis, Christina
    Snyder, Daniel
    Abedinzadeh, Laleh
    Bancroft, Tim
    Nesheim, Jeffrey
    [J]. NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S164 - S165
  • [3] Validity of a prescription claims database to estimate medication adherence in older persons
    Grymonpre, R
    Cheang, M
    Fraser, M
    Metge, C
    Sitar, DS
    [J]. MEDICAL CARE, 2006, 44 (05) : 471 - 477
  • [4] Synchronized Prescription Refills and Medication Adherence: A Retrospective Claims Analysis
    Doshi, Jalpa A.
    Lim, Raymond
    Li, Pengxiang
    Young, Peinie P.
    Lawnicki, Victor F.
    Troxel, Andrea B.
    Volpp, Kevin G.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (02): : 98 - +
  • [5] Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database
    Wagg, Adrian S.
    Foley, Steve
    Peters, John
    Nazir, Jameel
    Kool-Houweling, Leanne
    Scrine, Ludmila
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (10)
  • [6] Persistence and adherence with mirabegron versus antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice Prescription Database
    Wagg, Adrian
    Foley, Steve
    Peters, John
    Nazir, Jameel
    Kool-Houweling, Leanne
    Scrine, Ludmila
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 211 : 199 - 200
  • [7] Real-World Adherence and Persistence of Vibegron in Patients With Overactive Bladder: A Retrospective Claims Analysis
    Chastek, B.
    Carrera, A.
    Landis, C.
    Snyder, D.
    Abedinzadeh, L.
    Bancroft, T.
    Nesheim, J.
    Staskin, D.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 : S199 - S199
  • [8] Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis
    Chastek, Benjamin
    Carrera, Adam
    Landis, Christina
    Snyder, Daniel
    Abedinzadeh, Laleh
    Bancroft, Tim
    Nesheim, Jeffrey
    Kennelly, Michael
    Staskin, David
    [J]. ADVANCES IN THERAPY, 2024, 41 (05) : 2086 - 2097
  • [9] Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis
    Benjamin Chastek
    Adam Carrera
    Christina Landis
    Daniel Snyder
    Laleh Abedinzadeh
    Tim Bancroft
    Jeffrey Nesheim
    Michael Kennelly
    David Staskin
    [J]. Advances in Therapy, 2024, 41 : 2086 - 2097
  • [10] EFFECT OF ANTICHOLINERGIC BURDEN ON HEALTHCARE COSTS IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE DATABASE CLAIMS ANALYSIS
    Richter, H. E.
    Chastek, B.
    Carrera, A.
    Landis, C.
    Snyder, D.
    Abedinzadeh, L.
    Bancroft, T.
    Nesheim, J.
    Dmochowski, R. R.
    Hijaz, A. K.
    Frankel, J.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S103 - S103